Carrascosa J M, Molero J C, Fermín Y, Martínez C, Andrés A, Satrústegui J
Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC), Facultad de Ciencias, Universidad Autónoma, 28049 Madrid, Spain.
Diabetes Obes Metab. 2001 Aug;3(4):240-8. doi: 10.1046/j.1463-1326.2001.00102.x.
The effect of chronic treatment with acarbose on fasting plasma glucose, insulin, triglyceride, cholesterol and free fatty acid (FFA) concentrations, as well as on the glucose and insulin excursions during oral glucose tolerance test (OGTT), in obese diabetic Wistar (WDF) rats was investigated.
Forty-five mature male WDF rats were randomly distributed to one of the three treatment groups (no acarbose, 20 mg and 40 mg of acarbose/100 g of chow, respectively). After 3.5, 7.5 and 11.5 months, animals were tested for glucose tolerance by means of an OGTT, and their respective metabolic profiles were determined. Control determinations were done in obese and age-matched lean animals before the start of the trial.
The WDF rats exhibit higher body weight and fasting blood glucose, insulin, triglyceride and cholesterol concentrations compared to lean animals. Moreover, they show marked glucose intolerance as indicated by the glucose and insulin excursions during OGTT. Interestingly, in both treated and untreated animals, a reversion of the hyperglycaemic state as well as an improvement of the glucose tolerance is observed. However, whereas in the group receiving no acarbose this is accounted for by dramatic increases in fasting plasma insulin concentrations and insulin secretion during OGTT (as indicated by the DeltaInsulin area), in rats treated with acarbose the reversion of the diabetic state takes place without increments in hormone concentration. In addition, rats treated with acarbose for 3.5 and 7.5 months show lower plasma triglyceride and FFA concentrations, and the same was observed for cholesterol at the highest dosage of the drug.
Chronic treatment with acarbose of WDF rats improves the glycaemic and lipidic control as well as the glucose tolerance, with a lower demand of pancreatic insulin than in untreated rats. This data suggests that the long-term modulation of glucose and insulin excursions after meals improves the insulin sensitivity in this rat strain.
研究阿卡波糖长期治疗对肥胖糖尿病Wistar（WDF）大鼠空腹血糖、胰岛素、甘油三酯、胆固醇和游离脂肪酸（FFA）浓度的影响，以及对口服葡萄糖耐量试验（OGTT）期间血糖和胰岛素波动的影响。
45只成年雄性WDF大鼠随机分为三个治疗组之一（分别为不使用阿卡波糖、20mg和40mg阿卡波糖/100g食物）。在3.5、7.5和11.5个月后，通过OGTT对动物进行葡萄糖耐量测试，并测定其各自的代谢谱。在试验开始前，对肥胖和年龄匹配的瘦动物进行对照测定。
与瘦动物相比，WDF大鼠体重更高，空腹血糖、胰岛素、甘油三酯和胆固醇浓度更高。此外，OGTT期间的血糖和胰岛素波动表明它们存在明显的葡萄糖不耐受。有趣的是，在治疗组和未治疗组动物中，均观察到高血糖状态的逆转以及葡萄糖耐量的改善。然而，在未使用阿卡波糖的组中，这是由于空腹血浆胰岛素浓度的急剧增加以及OGTT期间胰岛素分泌增加（由DeltaInsulin面积表示）所致，而在使用阿卡波糖治疗的大鼠中，糖尿病状态的逆转在激素浓度未增加的情况下发生。此外，用阿卡波糖治疗3.5个月和7.5个月的大鼠血浆甘油三酯和FFA浓度较低，在该药物最高剂量下胆固醇也有同样表现。
WDF大鼠长期使用阿卡波糖治疗可改善血糖和血脂控制以及葡萄糖耐量，与未治疗的大鼠相比，对胰腺胰岛素的需求更低。该数据表明，餐后血糖和胰岛素波动的长期调节可改善该大鼠品系的胰岛素敏感性。
